Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Current Assets (2016 - 2025)

CytomX Therapeutics' Current Assets history spans 12 years, with the latest figure at $143.9 million for Q4 2025.

  • For Q4 2025, Current Assets rose 34.12% year-over-year to $143.9 million; the TTM value through Dec 2025 reached $143.9 million, up 34.12%, while the annual FY2025 figure was $143.9 million, 34.12% up from the prior year.
  • Current Assets reached $143.9 million in Q4 2025 per CTMX's latest filing, down from $149.2 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $400.0 million in Q1 2021 to a low of $86.6 million in Q1 2025.
  • Average Current Assets over 5 years is $201.6 million, with a median of $194.0 million recorded in 2022.
  • The largest YoY upside for Current Assets was 34.12% in 2025 against a maximum downside of 48.2% in 2025.
  • A 5-year view of Current Assets shows it stood at $310.3 million in 2021, then decreased by 23.59% to $237.1 million in 2022, then decreased by 22.85% to $182.9 million in 2023, then tumbled by 41.34% to $107.3 million in 2024, then soared by 34.12% to $143.9 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Current Assets are $143.9 million (Q4 2025), $149.2 million (Q3 2025), and $164.6 million (Q2 2025).